Robot-assisted radical cystectomy with totally intracorporeal neobladder diversion: perioperative, oncologic, and functional outcomes

The use of robot-assisted radical cystectomy (RARC) has increased rapidly in the past decade. However, reports of intracorporeal neobladder diversion remain limited. This article aimed to provide the surgical steps for RARC with totally intracorporeal neobladder diversion and the present perioperati...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Translational andrology and urology 2020-12, Vol.9 (6), p.2606-2615
Hauptverfasser: Gu, Qi, Xia, Jiadong, Xu, Aiming, Zhang, Tongtong, Wang, Zengjun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2615
container_issue 6
container_start_page 2606
container_title Translational andrology and urology
container_volume 9
creator Gu, Qi
Xia, Jiadong
Xu, Aiming
Zhang, Tongtong
Wang, Zengjun
description The use of robot-assisted radical cystectomy (RARC) has increased rapidly in the past decade. However, reports of intracorporeal neobladder diversion remain limited. This article aimed to provide the surgical steps for RARC with totally intracorporeal neobladder diversion and the present perioperative, oncologic, and functional outcomes. Between June 2017 and January 2020, RARC with intracorporeal neobladder diversion was performed in 12 male patients. Perioperative variables, pathologic data, early and late complications, urinary continence, potency, and recurrence-free survival were evaluated as outcome measures. The surgery was successful in all cases without open conversion. The median operative time, estimated blood loss, and postoperative hospital stay were 419 min (range, 315-640 min), 400 mL (range, 250-1,200 mL), and 14.5 days (range, 9-25 days), respectively. No positive surgical margins nor lymph nodes were observed. Eleven minor (grades 1 and 2) and one major (grades 3-5) complications were found in the early (0-30 days) period and six minor and one major complications in the late (>30 days) period. The median follow-up time was 13.1 months (range, 5.4-32.0 months), and two patients died due to metastatic disease. At 6 months after surgery, the daytime continence rate was 90.0%, while the nighttime continence rate was 80.0%. Only two patients (16.7%) reported capability of potency. The study was limited by a small sample size and short follow-up. RARC with intracorporeal neobladder is a complex procedure but technically feasible with acceptable oncologic and functional outcomes. Studies with long-term follow ups and increased number of cases and randomized trials are indispensable to assess the potential of this technique.
doi_str_mv 10.21037/tau-20-1075
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7807315</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478772649</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-8d22f8870550a0e51226304781184c36e5f5f7800b16d74459cdc41b8bc656c13</originalsourceid><addsrcrecordid>eNpVkU1rFTEUhoMottTuXEuWLu5oPidzXQhStAoFQdp1yJxk2khmzjXJVO4P8H83_bC0m3ycPHnPm7yEvOXsg-BMmo_VrZ1gHWdGvyCHQgjZqX7LXz5ZH5DjUn4zxriQg-r5a3IgpdJGSHlI_v3CEWvnSomlBk-z8xFcorBvW6g47-nfWK9oxepS2tO41OwA8w5zaNgScEzO-5Cpj9chl4jLJ7oLOWIbXG21DcUFMOFlhA11i6fTukBtXLuOawWcQ3lDXk0ulXD8MB-Ri29fz0--d2c_T3-cfDnroDmv3eCFmIbBMK2ZY0FzIXrJlBk4HxTIPuhJT2ZgbOS9N0rpLXhQfBxG6HUPXB6Rz_e6u3Wcg4dw-5pkdznOLu8tumifnyzxyl7itW2iRnLdBN4_CGT8s4ZS7RwLhJRc-4m1WNHMGCN6tW3o5h6FjKXkMD224czehWdbeFYwextew989tfYI_49K3gCjypkY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2478772649</pqid></control><display><type>article</type><title>Robot-assisted radical cystectomy with totally intracorporeal neobladder diversion: perioperative, oncologic, and functional outcomes</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Gu, Qi ; Xia, Jiadong ; Xu, Aiming ; Zhang, Tongtong ; Wang, Zengjun</creator><creatorcontrib>Gu, Qi ; Xia, Jiadong ; Xu, Aiming ; Zhang, Tongtong ; Wang, Zengjun</creatorcontrib><description>The use of robot-assisted radical cystectomy (RARC) has increased rapidly in the past decade. However, reports of intracorporeal neobladder diversion remain limited. This article aimed to provide the surgical steps for RARC with totally intracorporeal neobladder diversion and the present perioperative, oncologic, and functional outcomes. Between June 2017 and January 2020, RARC with intracorporeal neobladder diversion was performed in 12 male patients. Perioperative variables, pathologic data, early and late complications, urinary continence, potency, and recurrence-free survival were evaluated as outcome measures. The surgery was successful in all cases without open conversion. The median operative time, estimated blood loss, and postoperative hospital stay were 419 min (range, 315-640 min), 400 mL (range, 250-1,200 mL), and 14.5 days (range, 9-25 days), respectively. No positive surgical margins nor lymph nodes were observed. Eleven minor (grades 1 and 2) and one major (grades 3-5) complications were found in the early (0-30 days) period and six minor and one major complications in the late (&gt;30 days) period. The median follow-up time was 13.1 months (range, 5.4-32.0 months), and two patients died due to metastatic disease. At 6 months after surgery, the daytime continence rate was 90.0%, while the nighttime continence rate was 80.0%. Only two patients (16.7%) reported capability of potency. The study was limited by a small sample size and short follow-up. RARC with intracorporeal neobladder is a complex procedure but technically feasible with acceptable oncologic and functional outcomes. Studies with long-term follow ups and increased number of cases and randomized trials are indispensable to assess the potential of this technique.</description><identifier>ISSN: 2223-4691</identifier><identifier>ISSN: 2223-4683</identifier><identifier>EISSN: 2223-4691</identifier><identifier>DOI: 10.21037/tau-20-1075</identifier><identifier>PMID: 33457233</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original</subject><ispartof>Translational andrology and urology, 2020-12, Vol.9 (6), p.2606-2615</ispartof><rights>2020 Translational Andrology and Urology. All rights reserved.</rights><rights>2020 Translational Andrology and Urology. All rights reserved. 2020 Translational Andrology and Urology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-8d22f8870550a0e51226304781184c36e5f5f7800b16d74459cdc41b8bc656c13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807315/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807315/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33457233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gu, Qi</creatorcontrib><creatorcontrib>Xia, Jiadong</creatorcontrib><creatorcontrib>Xu, Aiming</creatorcontrib><creatorcontrib>Zhang, Tongtong</creatorcontrib><creatorcontrib>Wang, Zengjun</creatorcontrib><title>Robot-assisted radical cystectomy with totally intracorporeal neobladder diversion: perioperative, oncologic, and functional outcomes</title><title>Translational andrology and urology</title><addtitle>Transl Androl Urol</addtitle><description>The use of robot-assisted radical cystectomy (RARC) has increased rapidly in the past decade. However, reports of intracorporeal neobladder diversion remain limited. This article aimed to provide the surgical steps for RARC with totally intracorporeal neobladder diversion and the present perioperative, oncologic, and functional outcomes. Between June 2017 and January 2020, RARC with intracorporeal neobladder diversion was performed in 12 male patients. Perioperative variables, pathologic data, early and late complications, urinary continence, potency, and recurrence-free survival were evaluated as outcome measures. The surgery was successful in all cases without open conversion. The median operative time, estimated blood loss, and postoperative hospital stay were 419 min (range, 315-640 min), 400 mL (range, 250-1,200 mL), and 14.5 days (range, 9-25 days), respectively. No positive surgical margins nor lymph nodes were observed. Eleven minor (grades 1 and 2) and one major (grades 3-5) complications were found in the early (0-30 days) period and six minor and one major complications in the late (&gt;30 days) period. The median follow-up time was 13.1 months (range, 5.4-32.0 months), and two patients died due to metastatic disease. At 6 months after surgery, the daytime continence rate was 90.0%, while the nighttime continence rate was 80.0%. Only two patients (16.7%) reported capability of potency. The study was limited by a small sample size and short follow-up. RARC with intracorporeal neobladder is a complex procedure but technically feasible with acceptable oncologic and functional outcomes. Studies with long-term follow ups and increased number of cases and randomized trials are indispensable to assess the potential of this technique.</description><subject>Original</subject><issn>2223-4691</issn><issn>2223-4683</issn><issn>2223-4691</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkU1rFTEUhoMottTuXEuWLu5oPidzXQhStAoFQdp1yJxk2khmzjXJVO4P8H83_bC0m3ycPHnPm7yEvOXsg-BMmo_VrZ1gHWdGvyCHQgjZqX7LXz5ZH5DjUn4zxriQg-r5a3IgpdJGSHlI_v3CEWvnSomlBk-z8xFcorBvW6g47-nfWK9oxepS2tO41OwA8w5zaNgScEzO-5Cpj9chl4jLJ7oLOWIbXG21DcUFMOFlhA11i6fTukBtXLuOawWcQ3lDXk0ulXD8MB-Ri29fz0--d2c_T3-cfDnroDmv3eCFmIbBMK2ZY0FzIXrJlBk4HxTIPuhJT2ZgbOS9N0rpLXhQfBxG6HUPXB6Rz_e6u3Wcg4dw-5pkdznOLu8tumifnyzxyl7itW2iRnLdBN4_CGT8s4ZS7RwLhJRc-4m1WNHMGCN6tW3o5h6FjKXkMD224czehWdbeFYwextew989tfYI_49K3gCjypkY</recordid><startdate>202012</startdate><enddate>202012</enddate><creator>Gu, Qi</creator><creator>Xia, Jiadong</creator><creator>Xu, Aiming</creator><creator>Zhang, Tongtong</creator><creator>Wang, Zengjun</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202012</creationdate><title>Robot-assisted radical cystectomy with totally intracorporeal neobladder diversion: perioperative, oncologic, and functional outcomes</title><author>Gu, Qi ; Xia, Jiadong ; Xu, Aiming ; Zhang, Tongtong ; Wang, Zengjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-8d22f8870550a0e51226304781184c36e5f5f7800b16d74459cdc41b8bc656c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gu, Qi</creatorcontrib><creatorcontrib>Xia, Jiadong</creatorcontrib><creatorcontrib>Xu, Aiming</creatorcontrib><creatorcontrib>Zhang, Tongtong</creatorcontrib><creatorcontrib>Wang, Zengjun</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Translational andrology and urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gu, Qi</au><au>Xia, Jiadong</au><au>Xu, Aiming</au><au>Zhang, Tongtong</au><au>Wang, Zengjun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Robot-assisted radical cystectomy with totally intracorporeal neobladder diversion: perioperative, oncologic, and functional outcomes</atitle><jtitle>Translational andrology and urology</jtitle><addtitle>Transl Androl Urol</addtitle><date>2020-12</date><risdate>2020</risdate><volume>9</volume><issue>6</issue><spage>2606</spage><epage>2615</epage><pages>2606-2615</pages><issn>2223-4691</issn><issn>2223-4683</issn><eissn>2223-4691</eissn><abstract>The use of robot-assisted radical cystectomy (RARC) has increased rapidly in the past decade. However, reports of intracorporeal neobladder diversion remain limited. This article aimed to provide the surgical steps for RARC with totally intracorporeal neobladder diversion and the present perioperative, oncologic, and functional outcomes. Between June 2017 and January 2020, RARC with intracorporeal neobladder diversion was performed in 12 male patients. Perioperative variables, pathologic data, early and late complications, urinary continence, potency, and recurrence-free survival were evaluated as outcome measures. The surgery was successful in all cases without open conversion. The median operative time, estimated blood loss, and postoperative hospital stay were 419 min (range, 315-640 min), 400 mL (range, 250-1,200 mL), and 14.5 days (range, 9-25 days), respectively. No positive surgical margins nor lymph nodes were observed. Eleven minor (grades 1 and 2) and one major (grades 3-5) complications were found in the early (0-30 days) period and six minor and one major complications in the late (&gt;30 days) period. The median follow-up time was 13.1 months (range, 5.4-32.0 months), and two patients died due to metastatic disease. At 6 months after surgery, the daytime continence rate was 90.0%, while the nighttime continence rate was 80.0%. Only two patients (16.7%) reported capability of potency. The study was limited by a small sample size and short follow-up. RARC with intracorporeal neobladder is a complex procedure but technically feasible with acceptable oncologic and functional outcomes. Studies with long-term follow ups and increased number of cases and randomized trials are indispensable to assess the potential of this technique.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>33457233</pmid><doi>10.21037/tau-20-1075</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2223-4691
ispartof Translational andrology and urology, 2020-12, Vol.9 (6), p.2606-2615
issn 2223-4691
2223-4683
2223-4691
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7807315
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title Robot-assisted radical cystectomy with totally intracorporeal neobladder diversion: perioperative, oncologic, and functional outcomes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T13%3A46%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Robot-assisted%20radical%20cystectomy%20with%20totally%20intracorporeal%20neobladder%20diversion:%20perioperative,%20oncologic,%20and%20functional%20outcomes&rft.jtitle=Translational%20andrology%20and%20urology&rft.au=Gu,%20Qi&rft.date=2020-12&rft.volume=9&rft.issue=6&rft.spage=2606&rft.epage=2615&rft.pages=2606-2615&rft.issn=2223-4691&rft.eissn=2223-4691&rft_id=info:doi/10.21037/tau-20-1075&rft_dat=%3Cproquest_pubme%3E2478772649%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2478772649&rft_id=info:pmid/33457233&rfr_iscdi=true